Dr. Gupta highlights the FDA’s delays in approving critical treatments for cancers like pancreatic cancer and metastatic melanoma, despite promising results. These potential life-saving therapies are being held back, impacting patients with limited options. #FDA #CancerResearch

The FDA recently rejected a metastatic melanoma drug for conditional approval, citing its single arm trial design, despi... https://instagr.am/p/DXkWguAActk/

voteinorout on Instagram: "Dr. Gupta highlights the FDA’s delays in approving critical treatments for cancers like pancreatic cancer and metastatic melanoma, despite promising results. These potential life-saving therapies are being held back, impacting patients with limited options. #FDA #CancerResearch The FDA recently rejected a metastatic melanoma drug for conditional approval, citing its single arm trial design, despite a 40% tumor shrinkage response. This decision is surprising, as similar data was accepted in the past. For pancreatic cancer, an mRNA vaccine showed extraordinary results, with seven out of eight patients surviving past five years. Dr. Gupta emphasizes the urgent need for new options in treating these high-mortality diseases. — Dr. @vinguptaofficial breaks down how the FDA is delaying life-saving treatments for deadly cancers like pancreatic cancer and metastatic melanoma — even with promising results already in hand. Follow meidastouch for more. Help this information get to more voters. 🇺🇸 A well-informed electorate is a prerequisite to Democracy. - Thomas Jefferson"

59 likes, 0 comments - voteinorout on April 25, 2026: "Dr. Gupta highlights the FDA’s delays in approving critical treatments for cancers like pancreatic cancer and metastatic melanoma, despite promising results. These potential life-saving therapies are being held back, impacting patients with limited options. #FDA #CancerResearch The FDA recently rejected a metastatic melanoma drug for conditional approval, citing its single arm trial design, despite a 40% tumor shrinkage response. This decision is surprising, as similar data was accepted in the past. For pancreatic cancer, an mRNA vaccine showed extraordinary results, with seven out of eight patients surviving past five years. Dr. Gupta emphasizes the urgent need for new options in treating these high-mortality diseases. — Dr. @vinguptaofficial breaks down how the FDA is delaying life-saving treatments for deadly cancers like pancreatic cancer and metastatic melanoma — even with promising results already in hand. Follow meidastouch for more. Help this information get to more voters. 🇺🇸 A well-informed electorate is a prerequisite to Democracy. - Thomas Jefferson".

Instagram

Our mission has been to award projects that save lives

As Prof. June says, “The journey of CAR-T is a story of persistence, of radical collaboration and, most importantly, of the profound courage of the patients who enroll in our trials.

#innovation #cancercure #cancerresearch #cartcelltherapy

Crucially, this method helps address the "ancestry gap" by reducing the inherent biases found in smaller, human-designed gene panels.

Read the full study here:
https://www.nature.com/articles/s41698-026-01390-5 🔗

#PrecisionMedicine #Genomics #CancerResearch #HealthEquity #Bioinformatics

(3/3)

EXaCT-2: an augmented and customizable oncology-focused whole exome sequencing platform - npj Precision Oncology

We developed and benchmarked Exome Cancer Test v.2.0 (EXaCT-2), a novel whole-exome sequencing (WES) assay based on Agilent’s SureSelect hybrid-capture technology and expanded with custom probes targeting cancer-informative genomic regions. EXaCT-2 provides ~1,400 cancer genes with the depth of coverage typical of targeted panels, while achieving the genomic breadth to detect somatic copy number alterations (SCNAs), common cancer-related rearrangements, oncogenic viruses and B-cell receptor (BCR) clonotypes. Evaluated with a cancer patient cohort of 244 matched tumor/normal pairs and compared with clinically-validated results, EXaCT-2 achieved a mean sequencing depth of ~400× for critical cancer genes and ~100× for the remainder of the exome, with SCNA characterization showing improved boundary detection and overall segmentation. The assay demonstrated enhanced sensitivity for detecting sub-clonal, low-allele-frequency mutations missed by standard exome assays, such as mutations in GC-rich genes like KRAS. Analysis is performed by a modular, bespoke pipeline that leverages a workflow manager (Nextflow), in combination with containerized open-source tools. In addition to mutations and SCNAs, the pipeline reports common cancer rearrangements, hematologic oncogenic viruses, BCR clonotypes, and global molecular metrics, such as tumor mutational burden (TMB) and microsatellite instability (MSI). Collectively, these results establish EXaCT-2 as a comprehensive platform for integrated cancer genome profiling.

Nature

Why should we have to choose between the depth of a targeted panel and the breadth of whole-exome sequencing (WES)?

In our latest paper in npj Precision Oncology, we present a way to move beyond the limitations of traditional targeted panels.

(1/3)

#Genomics #PrecisionMedicine #Bioinformatics #CancerResearch #BioTech #npjPrecisionOncology

Africa: Pomegranate May Have Promising Health Benefits, but No Evidence Fruit Can Prevent or Treat Cancer: [Africa Check] Pomegranate may have promising health benefits, but no evidence fruit can prevent or treat cancer http://newsfeed.facilit8.network/TS94Rx #Pomegranate #HealthBenefits #CancerResearch #Nutrition #Superfood